Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules

PR Newswire

MADISON, Wis., May 29, 2026 /PRNewswire/ — Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Paul Miele, the company’s new Chief Commercial Officer and David Shin, the company’s new Chief Legal Officer.

As material inducements to Mr. Miele and Mr. Shin joining the company, and in accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee approved the granting of equity inducement awards to each of Mr. Miele and Mr. Shin, in each case effective as of May 29, 2026 (collectively, the “Inducement Awards”). The Inducement Awards were made outside of the company’s current equity plan but are subject to terms and conditions generally consistent with those in the company’s Stand‑Alone Inducement Restricted Stock Unit Agreement and the company’s 2026 Equity Incentive Plan.

Paul Miele Inducement Award
Mr. Miele was granted 650,000 restricted stock units (“RSUs”) covering shares of the company’s common stock. One fourth (1/4) of the underlying shares subject to the RSU award will vest on April 30, 2027 and will continue to vest as to one-fourth (1/4) of the underlying shares subject to the RSU award on each yearly anniversary of such date, subject in each case to Mr. Miele’s continued employment through the applicable vesting date.

In addition, Mr. Miele was granted 650,000 performance based restricted stock units (“PSUs”) (at target) covering shares of the company’s common stock. The PSUs have a performance period ending on the last day of the company’s 2028 fiscal year and will vest based on the achievement of performance criteria and other terms as determined by the Board of Directors or its Compensation Committee for performance based restricted stock units granted to other similarly situated senior executives, subject to Mr. Miele’s continued employment and the terms of the applicable award agreement.

David Shin Inducement Award
Mr. Shin was granted 375,000 restricted stock units (“RSUs”) covering shares of the company’s common stock. One‑fourth (1/4) of the underlying shares subject to the RSU award will vest on January 29, 2027 and will continue to vest as to one-fourth (1/4) of the underlying shares subject to the RSU award on each yearly anniversary of such date, subject in each case to Mr. Shin’s continued employment through the applicable vesting date.

In addition, Mr. Shin was granted 375,000 performance based restricted stock units (“PSUs”) (at target) covering shares of the company’s common stock. The PSUs have a performance period ending on the last day of the company’s 2028 fiscal year and will vest based on the achievement of performance criteria and other terms as determined by the Compensation Committee for performance based restricted stock units granted to other similarly situated senior executives of the company, subject to Mr. Shin’s continued employment and the terms of the applicable award agreement.

About Accuray
Accuray is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases—while making commonly treatable cases even easier—to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Sunnyvale, California, with facilities worldwide. To learn more, visit www.accuray.com or follow us on Facebook, LinkedIn, X, and YouTube.

Media Contact
Taylor Bould
Communications Specialist, Accuray
+1 (608) 830-3604
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/accuray-incorporated-reports-inducement-award-under-nasdaq-listing-rules-302786070.html

SOURCE Accuray Incorporated

Triumph Announces Dividend for 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock

Triumph Announces Dividend for 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock

DALLAS–(BUSINESS WIRE)–
Triumph (the “Company”) (NYSE: TFIN) today announced that the Company’s Board of Directors declared a quarterly cash dividend of $17.81 per share on its 7.125% Series C Fixed-Rate Non-Cumulative Perpetual Preferred Stock, represented by depositary shares (NYSE: TFIN-PR), each representing a 1/40th interest in a share of preferred stock. Holders of depositary shares will receive $0.44525 per depositary share. The dividend is payable on June 30, 2026, to holders of record at the close of business on June 15, 2026.

About Triumph Financial

Triumph (NYSE: TFIN) is a transportation-focused financial and technology company that delivers payments, factoring, banking, and intelligence solutions designed to simplify and modernize freight transactions for brokers, carriers, shippers and factors. The company develops technology and financial products that improve operational efficiency, increase transparency and security in transactions, and expand access to working capital across the transportation industry. Headquartered in Dallas, Texas, Triumph’s portfolio includes Triumph, LoadPay and TBK Bank. Learn more at www.triumph.io.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that such statements are predictions and that actual events or results may differ materially. Triumph Financial, Inc.’s expected financial results or other plans are subject to a number of risks and uncertainties. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” and the forward-looking statement disclosure contained in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission on February 11, 2026. Forward-looking statements speak only as of the date made and Triumph Financial undertakes no duty to update the information.

Investor Relations:

Luke Wyse

Executive Vice President, Head of Investor Relations

[email protected]

214-365-6936

Media Contact:

Amanda Tavackoli

Senior Vice President, Director of Corporate Communication

[email protected]

214-365-6930

KEYWORDS: Texas United States North America

INDUSTRY KEYWORDS: Data Management Banking Technology Professional Services Payments Trucking Transport Software Networks Logistics/Supply Chain Management Finance

MEDIA:

Logo
Logo

ALLIANCEBERNSTEIN GLOBAL HIGH INCOME FUND, INC. REPORTS FOURTH QUARTER EARNINGS

PR Newswire

NEW YORK, May 29, 2026 /PRNewswire/ — AllianceBernstein Global High Income Fund, Inc. (NYSE: AWF), a registered closed‑end investment company, today announced earnings for the fourth quarter ended March 31, 2026.

Total net assets of the Fund on March 31, 2026 were $963,393,828 as compared with $985,227,126 on December 31, 2025 and $966,409,431 on March 31, 2025. On March 31, 2026, the net asset value per share was $11.17 based on 86,229,677 shares of common stock outstanding.



March 31, 2026


December 31, 2025


March 31, 2025

Total Net Assets


$963,393,828

$985,227,126

$966,409,431

NAV Per Share


$11.17

$11.43

$11.21

Shares Outstanding          


86,229,677

86,229,677

86,229,677

For the period January 1, 2026 through March 31, 2026, total net investment income was $15,262,515 or $0.18 per share. The total net realized and unrealized loss was $(24,359,691) or $(0.28) per share for the same period.


Fourth
Quarter

      Ended



March 31, 2026

Third Quarter

      Ended


December 31, 2025

Fourth Quarter

      Ended


March 31, 2025

Total Net Investment

  Income                                         


$15,262,515

$15,059,136

$15,829,657

Per Share


$0.18

$0.17

$0.18

Total Net Realized/

  Unrealized Gain/(Loss)


$(24,359,691)

$(1,784,553)

$(10,907,723)

Per Share


$(0.28)

$(0.02)

$(0.13)

AllianceBernstein Global High Income Fund, Inc. is managed by AllianceBernstein L.P.

Cision View original content:https://www.prnewswire.com/news-releases/alliancebernstein-global-high-income-fund-inc-reports-fourth-quarter-earnings-302785961.html

SOURCE AllianceBernstein Global High Income Fund, Inc.

Fathom Holdings Inc. Receives Notification from Nasdaq Regarding Late Filing of Form 10-Q

PR Newswire

CARY, N.C., May 29, 2026 /PRNewswire/ — Fathom Holdings Inc. (Nasdaq: FTHM) (the “Company”), a national, technology-driven real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings, today announced that it has received a notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Rule”), because it has not timely filed its Quarterly Report on Form 10-Q for the period ended March 31, 2026 (the “Form 10-Q”) with the U.S. Securities and Exchange Commission (the “SEC”). The Rule requires Nasdaq-listed companies to timely file all required periodic financial reports with the SEC.

Nasdaq has provided the Company with 60 calendar days from the date of Notice, or until July 21, 2026, to submit a plan to regain compliance. If Nasdaq accepts the Company’s plan, then Nasdaq may grant the Company up to 180 days from the due date for the filing of the Form 10-Q, or until November 11, 2026, to regain compliance. However, there can be no assurance that Nasdaq will accept the Company’s plan to regain compliance or that the Company will be able to regain compliance within any extension period granted by Nasdaq. If Nasdaq does not accept the Company’s plan, then the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel.

The Notice has no immediate effect on the listing or trading of the Company’s securities. However, if the Company fails to timely regain compliance with the Rule, the Company’s securities will be subject to delisting from the Nasdaq Capital Market.

The Company is working diligently to finalize the financial statements and to file the Form 10-Q as soon as practicable.

About Fathom Holdings Inc.

Fathom Holdings Inc. is a national, technology-driven real estate services platform that integrates residential brokerage, mortgage, title, and SaaS offerings through its proprietary cloud-based software, intelliAgent. The Company’s brands include Fathom Realty, Encompass Lending, intelliAgent, Real Results, and Verus Title. For more information, visit www.FathomInc.com.

Cautionary Note Concerning Forward-Looking Statements

This press release contains “forward-looking statements” that involve risks and uncertainties which we expect will or may occur in the future and may impact our business, financial condition and results of operations. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including: reliance on, and risks associated with hiring, integrating and retaining, key personnel; risks associated with general economic conditions, including rising interest rates; its ability to generate positive operational cash flow; risks associated with the Company’s ability to continue achieving significant growth; its ability to continue its growth trajectory while achieving profitability over time; risks related to ongoing and future litigation; and other risks as set forth in the Risk Factors section of the Company’s most recent Form 10-K as filed with the SEC and supplemented from time to time in other Company filings made with the SEC. Copies of Fathom’s Form 10-K and other SEC filings are available on the SEC’s website, www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact:
Matt Glover and Clay Liolios
Gateway Group, Inc.
949-574-3860
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/fathom-holdings-inc-receives-notification-from-nasdaq-regarding-late-filing-of-form-10-q-302786014.html

SOURCE Fathom Holdings Inc.

Target Hospitality Announces Closing of Secondary Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

PR Newswire

THE WOODLANDS, Texas, May 29, 2026 /PRNewswire/ — Target Hospitality Corp. (“Target Hospitality” or the “Company”) (Nasdaq: TH), one of North America’s largest providers of vertically integrated modular accommodations and value-added hospitality services, today announced that it has closed its previously announced underwritten, secondary offering (the “Offering”) of 7,000,000 shares of its common stock, par value $0.0001 per share (the “Common Stock”), held by Arrow Holdings S.à r.l. and MFA Global S.à r.l. (collectively, the “Selling Stockholders”), entities controlled by TDR Capital LLP, acting in its capacity as investment fund manager, at a price to the public of $17.00 per share, as well as the full exercise by the underwriters of their option to purchase up to an additional 1,050,000 shares of Common Stock on the same terms and conditions, which closed concurrently. The Company did not sell any shares in the Offering and did not receive any of the proceeds from the Offering.

Morgan Stanley & Co. LLC and Deutsche Bank Securities Inc. acted as book-running managers for the Offering. Northland Securities, Inc., Oppenheimer & Co. Inc, Stifel, Nicolaus & Company, Incorporated and Texas Capital Securities are acting as co-managers for the Offering.

The Offering was made pursuant to an effective shelf registration statement on Form S-3, including a base prospectus, that was initially filed with the Securities and Exchange Commission (the “SEC”) on April 10, 2019 and subsequently declared effective by the SEC on May 16, 2019 and is available on the SEC’s website at www.sec.gov. The Offering was made only by means of a prospectus supplement and the accompanying prospectus that forms a part of the registration statement. A final prospectus supplement and the accompanying prospectus relating to the Offering has been filed with the SEC and is available on the SEC’s website. Copies of the final prospectus supplement and the accompanying prospectus may be obtained from: Morgan Stanley & Co. LLC, Attn: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, and Deutsche Bank Securities Inc., Attn: Prospectus Department, 1 Columbus Circle, New York, NY 10019, by telephone at (800) 503-4611, or by email at [email protected].

This press release does not constitute an offer to sell or a solicitation of an offer to buy any securities of the Company, nor shall there be any sale of securities of the Company in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Cautionary Statement Regarding Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside our control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include: operational, economic, including inflation, political and regulatory risks; our ability to effectively compete in the specialty rental accommodations and hospitality services industry, including growing the HFS – South, Workforce Hospitality Solutions and Government segments; our ability to execute, expand, and manage WHS projects supporting critical mineral development, power generation, and data center infrastructure projects; our ability to achieve margin improvement through the effective servicing of contracts in our WHS segment; effective management, utilization, and performance, of our communities (including workforce hubs); natural disasters and other business disruptions including outbreaks of epidemic or pandemic disease; the duration of any future public health crisis, related economic repercussions and the resulting negative impact to global economic demand; the effect of changes in state building codes on marketing our buildings; changes in demand within a number of key industry end-markets and geographic regions, including natural resources, critical minerals, and data center/AI infrastructure; changes in customer capital spending, project schedules, or end-user demand that may result in delays, non-renewals, or cancellations of contracts, including the contract that is terminable for convenience in the Government segment; our reliance on third party manufacturers, suppliers and service providers; our ability to attract and retain key personnel and maintain workforce availability for specialized hospitality and construction operations; increases in raw material, food, labor or other operating costs; the effect of impairment charges on our operating results; our future operating results fluctuating, failing to match performance or to meet expectations; our exposure to various possible claims and the potential inadequacy of our insurance coverage; unanticipated changes in our tax obligations; our obligations under various laws and regulations, including those applicable to government contracts; the effect of litigation, judgments, orders, regulatory or customer bankruptcy proceedings on our business; our ability to successfully acquire and integrate new operations; global, national or local economic and political developments, including any changes in policy under the current or any future U.S. presidential administrations; federal government budgeting and appropriations; our ability to manage credit risk and collect on our accounts receivable; our ability to fulfill Target Hospitality’s public company obligations; cybersecurity threats, incidents, or failures of our management information systems; and risks related to our liquidity, access to capital markets, and obligations under existing or future debt agreements, including compliance with financial covenants. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Contact Information

Investor Contact:
Mark Schuck
(832) 702 – 8009
[email protected]

Cision View original content:https://www.prnewswire.com/news-releases/target-hospitality-announces-closing-of-secondary-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares-302785991.html

SOURCE Target Hospitality

Jade Biosciences to Host Conference Call and Webcast on June 1, 2026, at 8:00 a.m. ET to Discuss Interim Phase 1 Healthy Volunteer Results for JADE101, a Novel, Potentially Best-in-Class Anti-APRIL Monoclonal Antibody in Development for IgA Nephropathy

SAN FRANCISCO and VANCOUVER, British Columbia, May 29, 2026 (GLOBE NEWSWIRE) — Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that it will host a conference call and webcast on Monday, June 1, 2026, at 8:00 a.m. ET to discuss results from the ongoing Phase 1 healthy volunteer study of JADE101. The data are expected to define the dosing strategy and further characterize JADE101’s clinical profile as a potentially differentiated, disease-modifying anti–A Proliferation-Inducing Ligand (APRIL) monoclonal antibody for the treatment of immunoglobulin A nephropathy (IgAN).

Conference Call and Webcast

Jade Biosciences will host a conference call and webcast on Monday, June 1, 2026, at 8:00 a.m. ET to discuss the JADE101 clinical data.

Investors and the general public are invited to listen to the live webcast and may register on the “Events and Presentations” page of the company’s website at JadeBiosciences.com. To join the live conference call, participants must register here. Upon registering, participants will receive dial-in details and a unique PIN to access the call. A replay of the webcast will be available on the Jade website shortly after the call concludes.

About IgA nephropathy (IgAN)

IgAN is a chronic autoimmune kidney disease that affects approximately 169,000 people in the U.S. and is most often diagnosed in young adults. The disease is characterized by the deposition of pathogenic IgA-containing immune complexes in the kidneys. These deposits can lead to increased protein in the urine, also known as proteinuria, declining kidney function, and potentially end-stage kidney disease requiring dialysis or a transplant. IgAN often requires lifelong treatment to preserve kidney function and prevent progression to kidney failure.

About JADE101 

JADE101 is a fully human monoclonal antibody that selectively blocks APRIL with ultra-high binding affinity and is engineered for half-life extension. Preclinical studies demonstrated potent, sustained IgA suppression after a single dose in non-human primates, with a serum half-life of approximately 27 days. JADE101 was designed to avoid formation of high molecular weight immune complexes, with the goal of supporting predictable pharmacokinetics and reduced immunogenicity risk. Its differentiated pharmacokinetic and pharmacodynamic profile supports the potential for infrequent and convenient subcutaneous dosing, an important consideration for a condition often diagnosed in young adulthood and potentially requiring life-long treatment. 

About Jade Biosciences, Inc.   
   
Jade Biosciences is a clinical-stage biotechnology company focused on developing best-in-class therapies that address critical unmet needs in autoimmune diseases. Jade’s lead candidate, JADE101, targets the cytokine APRIL, and is currently being evaluated for the treatment of immunoglobulin A nephropathy. Jade’s pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, as well as JADE301, an undisclosed antibody program. Jade was launched based on assets licensed from Paragon Therapeutics, an antibody discovery engine founded by Fairmount. For more information, visit JadeBiosciences.com and follow the Company on LinkedIn.   
   
Forward-Looking Statements

Certain statements in this communication, other than purely historical information, may constitute “forward-looking statements” within the meaning of the federal securities laws, including for purposes of the “safe harbor” provisions under the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Jade’s expectations, hopes, beliefs, intentions or strategies regarding the future of its pipeline and business including, without limitation, how the data from the ongoing Phase 1 healthy volunteer study of JADE101 will characterize JADE101’s clinical profile; the expected benefits or opportunities with respect to JADE101; the potential of JADE101 and Jade’s other product candidates to become best-in-class therapies; and the potential therapeutic uses, efficacy, durability, safety profiles, and dosing of JADE101. The words “opportunity,” “potential,” “milestones,” “pipeline,” “can,” “goal,” “strategy,” “target,” “anticipate,” “achieve,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “plan,” “possible,” “project,” “should,” “will,” “would” and similar expressions (including the negatives of these terms or variations of them) may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Jade will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Jade’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, the risks that the ongoing and any future clinical trials of JADE101 may be delayed or may not demonstrate desirable efficacy or clinical profile; adverse events and safety signals may occur; Jade’s product candidates may fail in development, may not receive required regulatory approvals, or may be delayed to a point where they are not commercially viable; enrollment or regulatory challenges; and the other risks, uncertainties and factors more fully described in Jade’s most recent filings with the Securities and Exchange Commission (including the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026). Should one or more of these risks or uncertainties materialize, or should any of Jade’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. You should not place undue reliance on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Jade does not undertake or accept any duty to release publicly any updates or revisions to any forward-looking statements. This communication does not purport to summarize all of the conditions, risks and other attributes of an investment in Jade.    

Jade Biosciences Contact   
  
Priyanka Shah   
[email protected]   
[email protected]   
908-447-6134 



Rocky Mountain Chocolate Factory Schedules Fiscal Fourth Quarter and Full Year 2026 Conference Call for June 2, 2026 at 9:00 A.M. ET

DURANGO, Colo., May 29, 2026 (GLOBE NEWSWIRE) — Rocky Mountain Chocolate Factory, Inc. (Nasdaq: RMCF) (the “Company”, “RMCF”, or “Rocky Mountain Chocolate Factory”), America’s Chocolatier™ will host a conference call on Tuesday, June 2, 2026 at 9:00 a.m. Eastern time to discuss its fiscal fourth quarter and full year 2026 results. The Company’s results will be reported in a press release prior to the call.

The RMCF management team will host the conference call, followed by a question-and-answer period. Attendees are invited to submit questions ahead of the call by emailing the Company’s investor relations team at [email protected]. The conference call details are as follows:

Date: Tuesday, June 2, 2026
Time: 9:00 a.m. Eastern time
Dial-in registration link: here
Live webcast registration link: here

Please dial into the conference call 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact the Company’s investor relations team at [email protected].

The conference call will also be broadcast live and available for replay in the investor relations section of the Company’s website at https://ir.rmcf.com/.

About Rocky Mountain Chocolate Factory, Inc.


R
ocky Mountain Chocolate Factory, Inc.
is a leading franchisor of premium chocolate and confectionary retail store concept. As America’s Chocolatier™, the Company has been producing an extensive line of premium chocolates and other confectionery products, including gourmet caramel apples since 1981. Headquartered in Durango, Colorado, Rocky Mountain Chocolate Factory is ranked among Entrepreneur’s Franchise 500® for 2026. The Company and its franchisees and licensees operate over 250 Rocky Mountain Chocolate stores across the United States, with several international locations. The Company’s common stock is listed on the Nasdaq Global Market under the symbol “RMCF.”

Investor Contact
Sean Mansouri, CFA
Elevate IR
720-330-2829
[email protected]



Asana to Present at Upcoming Investor Events

Asana to Present at Upcoming Investor Events

SAN FRANCISCO–(BUSINESS WIRE)–
Asana, Inc. (NYSE: ASAN)(LTSE: ASAN), the operating system for human-agent teams, today announced that Asana’s executives will present at the following investor events:

  • Bank of America 2026 Global Technology Conference on June 2, 2026 at 10:40 a.m. PT / 1:40 p.m. ET

  • Baird 2026 Global Consumer, Technology & Services Conference on June 4, 2026 at 6:40 a.m. PT / 9:40 a.m. ET

  • Asana Investor Webinar: OS for Human-Agent Teams – Strategy and Innovation Showcase on June 8, 2026 at 7:00 a.m. PT / 10:00 a.m. ET

A live webcast will be available on Asana’s website at https://investors.asana.com.

About Asana

Asana is the operating system for human-agent teams. Built on the Enterprise Work Graph and 18 years of multiplayer architecture, Asana is where an organization’s humans and agents run critical workflows together – from a shared plan, with shared memory, all under enterprise-grade governance. Learn more at asana.com.

Eva Leung

Asana Investor Relations

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Technology Human Resources Other Technology Accounting Business Professional Services Software Data Management Artificial Intelligence

MEDIA:

Logo
Logo

Empire State Realty Trust to Present at The Nareit REITweek 2026 Investor Conference

Empire State Realty Trust to Present at The Nareit REITweek 2026 Investor Conference

NEW YORK–(BUSINESS WIRE)–
Empire State Realty Trust, Inc. (NYSE: ESRT) (the “Company”), today announced that Christina Chiu, President, Steve Horn, EVP, Chief Financial Officer, and Ryan Kass, EVP, Co-head and Chief Revenue Officer of Real Estate, will participate in a moderated Company presentation at the Nareit REITweek 2026 investor conference on Tuesday, June 2, 2026, from 1:45 p.m. to 2:15 p.m. Eastern Time. The Company presentation will be available via webcast. The live audio-webcast can be accessed in listen-only mode on the “Investors” section of the Company’s website (www.esrtreit.com) under “Presentations”. A replay of the audio-webcast will be available through August 1st, 2026, via the same link.

About Empire State Realty Trust

Empire State Realty Trust, Inc. (NYSE: ESRT) is a NYC-focused REIT that owns and operates a portfolio of well-leased, top of tier, modernized, amenitized, and well-located office, retail, and multifamily assets. ESRT’s flagship Empire State Building, the “World’s Most Famous Building,” features its iconic Observation Deck, ranked the #1 Top Attraction in the United States in Tripadvisor’s 2026 Travelers’ Choice Awards: Best of the Best Things to Do. The Company is a recognized leader in energy efficiency and indoor environmental quality. As of March 31, 2026, ESRT’s portfolio is comprised of approximately 8.0 million rentable square feet of office space, 0.8 million rentable square feet of retail space and 743 residential units. More information about Empire State Realty Trust can be found at esrtreit.com and by following ESRT on Facebook, Instagram, TikTok, X, and LinkedIn.

Category: GENERAL

Investors

Empire State Realty Trust Investor Relations

(212) 850-2678

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Logo
Logo

AMGEN TO PRESENT AT JEFFERIES GLOBAL HEALTHCARE CONFERENCE

PR Newswire

THOUSAND OAKS, Calif., May 29, 2026 /PRNewswire/ — Amgen (NASDAQ:AMGN) will present at Jefferies Global Healthcare Conference at 9:55 a.m. ET on Thursday, June 4, 2026. Peter Griffith, executive vice president and chief financial officer at Amgen, Narimon Honarpour, senior vice president of global development at Amgen, and Kave Niksefat, senior vice president of Global Marketing and Access at Amgen, will present at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen
Amgen discovers, develops, manufactures and delivers innovative medicines to fight some of the world’s toughest diseases. Harnessing the best of biology and technology, Amgen reaches millions of patients with its medicines.

More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic data to push beyond what is known today. Amgen is advancing a broad and deep pipeline and portfolio of medicines to treat cancer, inflammatory conditions, rare diseases, heart disease and obesity and obesity-related conditions.

Amgen has been consistently recognized for innovation and workplace culture, including honors from Fast Company and Forbes. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average®, and it is also part of the Nasdaq-100 Index®, which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization.

For more information, visit Amgen.com and follow Amgen on XLinkedInInstagramYouTubeFacebookTikTok and Threads.

CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media) 
Casey Capparelli, 805-447-1746 (investors)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-present-at-jefferies-global-healthcare-conference-302785887.html

SOURCE Amgen